Open AccessThe Clinical Utility of DCISionRT® on Radiation Therapy Decision Making in Patients with Ductal Carcinoma In Situ Following Breast-Conserving Surgery
Author(s) -
Chirag Shah,
Troy Bremer,
Charles E. Cox,
Pat W. Whitworth,
Rakesh Patel,
Anushka Patel,
Erin G. Brown,
Linsey Gold,
David T. Rock,
Lee B. Riley,
Christy Kesslering,
Sheree Brown,
Robert Gabordi,
JV Pellicane,
Rachel Rabinovich,
Sadia Khan,
Sandra Templeton,
Lonika Majithia,
Shawna C. Willey,
Fredrik Wärnberg,
Naamit K. Gerber,
Steve Shivers,
Frank A. Vicini
Publication year - 2021
Publication title -
annals of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.764
H-Index - 173
eISSN - 1534-4681
pISSN - 1068-9265
DOI - 10.1245/s10434-021-09903-1
Subject(s) - medicine , surgical oncology , ductal carcinoma , radiation therapy , breast cancer , mastectomy , breast conserving surgery , oncology , general surgery , breast surgery , surgery , cancer
The role of radiation therapy (RT) following breast-conserving surgery (BCS) in ductal carcinoma in situ (DCIS) remains controversial. Trials have not identified a low-risk cohort, based on clinicopathologic features, who do not benefit from RT. A biosignature (DCISionRT ® ) that evaluates recurrence risk has been developed and validated. We evaluated the impact of DCISionRT on clinicians' recommendations for adjuvant RT.